文献速递前列腺癌

转移性去势抵抗性前列腺癌中基于免疫组化的雄激素受体状态与AR阴性表型评估

Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-02-24

该研究对27例转移性去势抵抗性前列腺癌(mCRPC)病例进行分子与免疫组化分析,排除神经内分泌分化,评估AR、P53、RB免疫组化与AR基因改变的相关性。结果显示17例AR扩增且核AR表达阳性,5例(另1例NGS失败)呈AR阴性表型,常伴TP53、RB1、PTEN共改变,且均接受过AR信号抑制剂治疗。结论提示AR免疫组化可区分AR阴性/阳性,辅助临床决策。

要点

  • AR免疫组化可区分mCRPC中AR阴性表型与AR表达病例。
  • AR阴性表型常伴TP53、RB1、PTEN改变,且均用过AR信号抑制剂。
  • AR免疫组化可作为有限组织或分子检测不可及时的成本效益策略。

核心结论

  • AR免疫组化可能区分转移性前列腺癌中的AR阴性及AR表达病例。
  • AR阴性状态有助于决定是否继续AR信号抑制剂治疗及考虑其他方案。

研究设计与样本

  • 回顾性评估27例转移性去势抵抗性前列腺癌病例,经组织病理学排除神经内分泌分化。
  • 采用外显子捕获NGS(n=26)、FISH检测AR拷贝数(n=16)及免疫组化检测AR(n=27)、P53(n=24)、RB(n=25)。

主要发现

  • 27例中17例有AR扩增且免疫组化核AR表达阳性。
  • 9例NGS/FISH未见AR拷贝数改变,其中5例(另1例NGS失败)免疫组化呈AR阴性表型。
  • AR阴性病例常见TP53、RB1、PTEN共改变,且所有患者均接受过阿比特龙和/或恩扎卢胺治疗。

临床怎么用

  • 对mCRPC病例可考虑AR免疫组化辅助识别AR阴性表型。
  • AR阴性状态提示可能需停用AR信号抑制剂并考虑其他治疗选择。
  • 在分子检测受限或肿瘤组织不足时,AR免疫组化可能是经济有效的诊断策略。

局限性

  • 样本量较小(27例),部分检测项目存在缺失数据(如NGS失败1例)。
  • 研究为回顾性设计,未报告前瞻性验证或生存结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Molecular and immunohistochemistry-based profiling of prostatic adenocarcinoma has revealed frequent Androgen Receptor (AR) gene and protein alterations in metastatic disease. This includes an AR-null non-neuroendocrine phenotype of metastatic castrate resistant prostate cancer which may be less sensitive to androgen receptor signaling inhibitors. This AR-null non-neuroendocrine phenotype is thought to be associated with TP53 and RB1 alterations. Herein, we have correlated molecular profiling of metastatic castrate resistant prostate cancer with AR/P53/RB immunohistochemistry and relevant clinical correlates. DESIGN: Twenty-seven cases of metastatic castrate resistant prostate cancer were evaluated using histopathologic examination to rule out neuroendocrine differentiation. A combination of a hybridization exon-capture next-generation sequencing-based assay (n = 26), fluorescence in situ hybridization for AR copy number status (n = 16), and immunohistochemistry for AR (n = 27), P53 (n = 24) and RB (n = 25) was used to profile these cases. RESULTS: Of 27 metastatic castrate resistant prostate cancer cases, 17 had AR amplification and showed positive nuclear expression of AR by immunohistochemistry. Nine cases lacked AR copy number alterations using next-generation sequencing/fluorescence in situ hybridization. A subset of these metastatic castrate resistant prostate cancer cases demonstrated the AR-null phenotype by immunohistochemistry (five cases and one additional case where next-generation sequencing failed). Common co-alterations in these cases involved the TP53, RB1, and PTEN genes and all these patients received prior therapy with androgen receptor signaling inhibitors (abiraterone and/or enzalutamide). CONCLUSIONS: Our study suggests that AR immunohistochemistry may distinguish AR-null from AR-expressing cases in the metastatic setting. AR-null status informs clinical decision-making regarding continuation of therapy with androgen receptor signaling inhibitors and consideration of other treatment options. This might be a relevant and cost-effective diagnostic strategy when there is limited access and/or limited tumor material for molecular testing.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Gupta S, Vanderbilt C, Abida W, et al. Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020. PMID: 32094488. doi:10.1038/s41391-020-0214-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。